Novartis is committed to conducting a large outcome trial program to evaluate the long-term effects of Tekturna and direct renin inhibition.In September 2006, Tekturna, which will be known as Rasilez outside the United States, presented the European Medicines Agency for the review in the European Union. Tekturna was developed in collaboration with Speedel. – Disclaimer.
Novartis is providing the information in this press release as of this date and does not undertake to update forward-looking statements press release as a press release as a result of of new information, future events or otherwise.. This press release contains forward looking statements by the use of terminology such as potential, commitment to development , committed to the implementation , evaluate , can be identified, expects , will or similar expressions, or by express or implied discussions regarding the long-term effects of Tekturna and direct renin inhibition, potential future approval of Tekturna, or future sales. Such forward looking statements involve known and unknown risks, factors thatainties and other factors that lead to the actual results expressed materially from any future results, performance or achievements expressed or implied by such statements vary.Forward-looking statements reflect the current views and based on certain assumptions and expectations base. Such statements will include, among others statements regarding the preliminary results, the clinic schedules and prospects for Genaera applications including ingredient is trodusquemine and of IL – 9 antibody software. This of these forward-looking statements of the use of words expressed in such statements such as identifying anticipate , believe , continue , developing , expect , plan and potential or in other words of similar meaning.